A Phase 2 interventional study of VP-102 in Common Warts, Common Warts (Verruca Vulgaris) and Human Papilloma Virus (HPV), sponsored by Verrica Pharmaceuticals Inc.. Not yet recruiting at 4 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Verrica Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal application in subjects with common warts.
184 studies on the registry are indexed under Warts; 29 are open to participants now.
This study's planned enrollment of 30 is below the median of 70 across 163 interventional studies indexed under Warts.
Browse Warts studies →Verrica Pharmaceuticals Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Topical solution, which is a light violet to dark purple, slightly viscous liquid. Each single-use applicator contains 0.45 mL of 0.7% w/v cantharidin. VP-102 will be administered topically as a single application on Day 1 using no more than 2 applicators.
Combination Product: VP-102
YCANTH (VP-102) is supplied as a topical solution containing cantharidin 0.7% w/v in a single-use glass ampule applicator. The solution will be applied to the entirety of each common wart selected for treatment, including an approximate 1 to 2 mm margin of surrounding healthy skin. No more than 2 applicators may be used. Occlusive tape will be applied after the solution has dried and will remain in place overnight until removal at approximately 24 hours.
Proportion of subjects exhibiting systemic exposure to YCANTH (VP-102)
The proportion of subjects exhibiting systemic cantharidin exposure following a single application of YCANTH (VP-102), based on plasma samples collected before application of study drug and at 2, 6, and 24 hours after application.
Time frame: Predose, 2 hours, 6 hours, and 24 hours after study drug application
Incidence and severity of adverse events including local skin reactions
Number and percentage of subjects experiencing treatment-emergent adverse events (TEAEs), including local skin reactions (LSRs), and assessment of event severity.
Time frame: From study drug application on Day 1 through Day 21
Change from baseline in pulse rate
Change from baseline in pulse rate.
Time frame: Baseline through Day 21
Change from baseline in body temperature
Change from baseline in body temperature.
Time frame: Baseline through Day 21
Concomitant medication use
Number and percentage of subjects reporting concomitant medication use after study drug application.
Time frame: From study drug application on Day 1 through Day 21
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VP-102
Verrica Pharmaceuticals Inc.